These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 31219884)
41. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Levin CY; Maibach H Am J Clin Dermatol; 2001; 2(4):213-7. PubMed ID: 11705248 [TBL] [Abstract][Full Text] [Related]
42. Probable coexisting exogenous ochronosis and mercurial pigmentation managed by dermabrasion. Lang PG J Am Acad Dermatol; 1988 Nov; 19(5 Pt 2):942-6. PubMed ID: 3192777 [TBL] [Abstract][Full Text] [Related]
43. The widespread use of skin lightening creams in Senegal: a persistent public health problem in West Africa. del Giudice P; Yves P Int J Dermatol; 2002 Feb; 41(2):69-72. PubMed ID: 11982639 [TBL] [Abstract][Full Text] [Related]
44. Glaucoma With Alkaptonuria as a Result of Pigment Accumulation. Okutucu M; Aslan MG; Findik H; Yavuz G J Glaucoma; 2019 Jul; 28(7):e112-e114. PubMed ID: 31274704 [TBL] [Abstract][Full Text] [Related]
47. Exogenous Ochronosis: Characterizing a Rare Disorder in Skin of Color. Lazar M; De La Garza H; Vashi NA J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445377 [TBL] [Abstract][Full Text] [Related]
48. A case of ochronosis successfully treated with the picosecond laser. Méndez Baca I; Al-Niaimi F; Colina C; Anuzita A J Cosmet Dermatol; 2019 Oct; 18(5):1322-1325. PubMed ID: 30556284 [TBL] [Abstract][Full Text] [Related]
49. Hydroquinone for skin lightening: safety profile, duration of use and when should we stop? Tse TW J Dermatolog Treat; 2010 Sep; 21(5):272-5. PubMed ID: 20095963 [TBL] [Abstract][Full Text] [Related]
50. Widespread use of toxic skin lightening compounds: medical and psychosocial aspects. Ladizinski B; Mistry N; Kundu RV Dermatol Clin; 2011 Jan; 29(1):111-23. PubMed ID: 21095535 [TBL] [Abstract][Full Text] [Related]
51. Ochronosis: a case of severe ochronotic arthropathy. Nas K; Gür A; Akdeniz S; Cevik R; Harman M; Saraç AJ Clin Rheumatol; 2002 May; 21(2):170-2. PubMed ID: 12086170 [TBL] [Abstract][Full Text] [Related]
52. Exogenous ochronosis: an epidemiological study. Hardwick N; Van Gelder LW; Van der Merwe CA; Van der Merwe MP Br J Dermatol; 1989 Feb; 120(2):229-38. PubMed ID: 2923796 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening. Draelos ZD; Yatskayer M; Bhushan P; Pillai S; Oresajo C Cutis; 2010 Sep; 86(3):153-8. PubMed ID: 21049734 [TBL] [Abstract][Full Text] [Related]
54. Cosmetic ochronosis caused by bleaching creams containing 2% hydroquinone. Weiss RM; del Fabbro E; Kolisang P S Afr Med J; 1990 Apr; 77(7):373. PubMed ID: 2321111 [No Abstract] [Full Text] [Related]
57. [Role of dermoscopy and reflectance confocal microscopy as an aid in the diagnosis of exogenous ochronosis]. Cinotti E; Labeille B; Douchet C; Cambazard F; Perrot JL; Ann Dermatol Venereol; 2016 Apr; 143(4):318-20. PubMed ID: 26988381 [No Abstract] [Full Text] [Related]
58. Descemet's membrane folds in ochronosis: a case report. de Azevedo Magalhaes O; Abdel Rahman Abu Hwas D J Med Case Rep; 2022 Oct; 16(1):351. PubMed ID: 36183119 [TBL] [Abstract][Full Text] [Related]
60. Chronic hydroquinone poisoning of the skin from skin-lightening cosmetics. A South African epidemic of ochronosis of the face in dark-skinned individuals. Findlay GH; de Beer HA S Afr Med J; 1980 Feb; 57(6):187-90. PubMed ID: 7361208 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]